ClinicalTrials.gg
TerminatedNCT01545050Updated Dec 3, 2021Results posted

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

A Phase 2 interventional study of Placebo matching with BMS-945429 and Placebo matching with BMS-945429 in Crohn's Disease, sponsored by CSL Behring. Terminated at 56 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
due to sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
242nd of 528
72 · median 60
Started
2012
with 24 others
Phase 2
141 of 660
23 open now
Registered
203rd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 242nd largest by enrollment of the 528 interventional ones that give a count, is one of 25 that started in 2012, is one of 141 in phase 2, and was the 203rd registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed Crohn's Disease diagnosis via radiology, endoscopy or histology within prior 12 months. Diagnosed for at least 3 months
  • Active Disease with Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450
  • Failed conventional therapy or dependent

Exclusion criteria

Exclusion Criteria:

  • Diagnosed/clinical findings of Ulcerative Colitis (UC), indeterminate colitis, non colonic/ileal disease
  • Stricture/stenosis, Stoma, proctocolectomy, subtotal colectomy, ileorectal anastomosis
  • History of diverticulitis, or evidence of Gastrointestinal (GI) perforations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Induction Cohort: Placebo matching with BMS-945429 (Clazakizumab)

    Biological: Placebo matching with BMS-945429

  • Experimental
    Induction Cohort: BMS-945429 (Clazakizumab)(600 IV/200 SC mg)

    Biological: Placebo matching with BMS-945429 · Biological: BMS-945429

  • Experimental
    Induction Cohort: BMS-945429 (Clazakizumab)(300 IV/100 SC mg)

    Biological: Placebo matching with BMS-945429 · Biological: BMS-945429

  • Experimental
    Induction Cohort: BMS-945429 (Clazakizumab)(150 IV/100 SC mg)

    Biological: Placebo matching with BMS-945429 · Biological: BMS-945429

  • Experimental
    Induction Cohort: BMS-945429 (Clazakizumab)(400 SC/200 SC mg)

    Biological: Placebo matching with BMS-945429 · Biological: BMS-945429

  • Experimental
    Maintenance Cohort: Placebo matching with BMS-945429 (Clazakizumab)

    Biological: Placebo matching with BMS-945429

  • Experimental
    Maintenance Cohort: BMS-945429 (Clazakizumab)(100 SC mg)

    Biological: BMS-945429

  • Experimental
    Maintenance Cohort: BMS-945429 (Clazakizumab)(200 SC mg)

    Biological: BMS-945429

  • Experimental
    Open Label Cohort: BMS-945429 (Clazakizumab)(200 SC mg)

    Biological: BMS-945429

Interventions

  • BiologicalPlacebo matching with BMS-945429

    Injection, Intravenous (IV), 0 mg, Day One Only, One Day

  • BiologicalPlacebo matching with BMS-945429

    Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks

  • BiologicalPlacebo matching with BMS-945429

    Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day

  • BiologicalPlacebo matching with BMS-945429

    Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks

  • BiologicalBMS-945429

    Injection, Intravenous (IV), 600 mg, Day One Only, One Day

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Intravenous (IV), 300 mg, Day One Only, One Day

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Intravenous (IV), 150 mg, Day One Only, One Day

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks

    Also known as: Clazakizumab

  • BiologicalBMS-945429

    Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period

    Also known as: Clazakizumab

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Clinical Remission (CDAI<150) as Measured by the Crohn's Disease Activity Index (CDAI)

    CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity

    Time frame: At 8 weeks during the Induction Period

Secondary outcomes

  1. Percent of Participants With Clinical Response (>100 Point Decrease in CDAI) During Induction Period as Measured by CDAI

    CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity

    Time frame: At 8 weeks during the Induction Period

  2. Change From Baseline at Week 8 and 12 of Inflammatory Bowel Disease Questionnaire (IBDQ) Score

    IBDQ consists of 32 questions divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.

    Time frame: Week 8 and Week 12

  3. Number of Participants During the Induction Period With Anti-clazakizumab Antibodies

    Time frame: Up to Week 12

  4. Steady-state Trough Concentration (Cmin) of Clazakizumab During the Induction Period

    Time frame: Week 4, Week 8

  5. Observed Maximum Concentration (Cmax) of Clazakizumab During the Induction Period

    Time frame: Week 0 and Week 4

  6. Area Under the Plasma Concentration-time Curve in One Dosing Interval [AUC(TAU)] of Clazakizumab During the Induction Period

    Time frame: Week 0, Week 4, Week 8

07

Results

Posted Dec 3, 2021
Limitations and caveats
The interpretation of the PK analysis is limited for several reasons. First, the concentration data that was collected only allowed for reporting of Cmin concentrations. Second, the sample size was limited.

Participant flow

Participant flow — Overall Study
MilestonePlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Started18991818
Completed114469
Not completed755129
Withdrew: Lack of efficacy00032
Withdrew: Adverse event11220
Withdrew: Discontinued study treatment10000
Withdrew: Withdrawal by subject10021
Withdrew: Participant no longer meets study criteria02001
Withdrew: Administrative reason by sponsor42355

Outcome measures

PrimaryPercent of Participants With Clinical Remission (CDAI<150) as Measured by the Crohn's Disease Activity Index (CDAI)

CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity

Time frame:
At 8 weeks during the Induction Period
Reported as:
Number · percentage of participants
Percent of Participants With Clinical Remission (CDAI<150) as Measured by the Crohn's Disease Activity Index (CDAI)
percentage of participantsPlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Percent of Participants With Clinical Remission (CDAI<150) as Measured by the Crohn's Disease Activity Index (CDAI)17.633.3018.812.5
SecondaryPercent of Participants With Clinical Response (>100 Point Decrease in CDAI) During Induction Period as Measured by CDAI

CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity

Time frame:
At 8 weeks during the Induction Period
Reported as:
Number · percentage of participants
Percent of Participants With Clinical Response (>100 Point Decrease in CDAI) During Induction Period as Measured by CDAI
percentage of participantsPlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Percent of Participants With Clinical Response (>100 Point Decrease in CDAI) During Induction Period as Measured by CDAI29.433.325.031.312.5
SecondaryChange From Baseline at Week 8 and 12 of Inflammatory Bowel Disease Questionnaire (IBDQ) Score

IBDQ consists of 32 questions divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.

Time frame:
Week 8 and Week 12
Reported as:
Mean · score on a scale
Change From Baseline at Week 8 and 12 of Inflammatory Bowel Disease Questionnaire (IBDQ) Score
score on a scalePlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Week 811.8 ± 23.01-2.0 ± 28.931.9 ± 36.4615.5 ± 32.0114.8 ± 33.7
Week 1210.0 ± 33.6521.8 ± 34.621.4 ± 61.0620.1 ± 36.3218.7 ± 35.62
SecondaryNumber of Participants During the Induction Period With Anti-clazakizumab Antibodies
Time frame:
Up to Week 12
Reported as:
Number · participants
Number of Participants During the Induction Period With Anti-clazakizumab Antibodies
participantsPlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Number of Participants During the Induction Period With Anti-clazakizumab Antibodies00001
SecondarySteady-state Trough Concentration (Cmin) of Clazakizumab During the Induction Period
Time frame:
Week 4, Week 8
Reported as:
Mean · ug/mL
Steady-state Trough Concentration (Cmin) of Clazakizumab During the Induction Period
ug/mLClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Week 4——21.0816 ± 8.19326—
Week 8——36.1026 ± 14.49349—
SecondaryObserved Maximum Concentration (Cmax) of Clazakizumab During the Induction Period
Time frame:
Week 0 and Week 4

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration-time Curve in One Dosing Interval [AUC(TAU)] of Clazakizumab During the Induction Period
Time frame:
Week 0, Week 4, Week 8

No measurements were reported for this outcome.

Adverse events

Collected over Up to 12 weeks per participant. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)2/18 (11.1%)1/18 (5.6%)
Clazakizumab (150 IV/100 SC)0/9 (0%)2/9 (22.2%)2/9 (22.2%)
Clazakizumab (300 IV/100 SC)1/9 (11.1%)2/9 (22.2%)3/9 (33.3%)
Clazakizumab (400 SC/200 SC)0/18 (0%)6/18 (33.3%)8/18 (44.4%)
Clazakizumab (600 IV/200 SC)0/18 (0%)4/18 (22.2%)2/18 (11.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Cronh's diseaseGastrointestinal disorders0/181/90/92/183/18
Intestinal perforationGastrointestinal disorders0/180/91/90/181/18
Large intestine perforationGastrointestinal disorders0/181/90/90/180/18
PeritonitisInfections and infestations0/180/91/90/181/18
ErysipelasInfections and infestations0/180/91/90/180/18
Pelvic abscessInfections and infestations0/181/90/90/180/18
Septic shockInfections and infestations0/180/91/90/180/18
PericarditisCardiac disorders0/181/90/90/180/18
Anal fistulaGastrointestinal disorders1/180/90/91/180/18
Anorectal disorderGastrointestinal disorders0/180/90/91/180/18
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)
Injection site erythemaGeneral disorders0/180/90/92/181/18
Injection site reactionGeneral disorders0/180/90/92/180/18
Chest painGeneral disorders0/180/91/90/180/18
ErysipelasInfections and infestations0/180/91/90/180/18
PeritonitisInfections and infestations0/180/91/90/180/18
Septic shockInfections and infestations0/180/91/90/180/18
Vulvovaginal candidiasisInfections and infestations0/181/90/90/180/18
Dry skinSkin and subcutaneous tissue disorders0/180/91/90/180/18
Nail dystrophySkin and subcutaneous tissue disorders0/181/90/90/180/18
PurpuraSkin and subcutaneous tissue disorders0/180/91/90/180/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)Total
<=18 years000000
Between 18 and 65 years1798181769
>=65 years101013
Age, Continuous
Age, Continuous(years)PlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)Total
Mean41.1 ± 11.7036.3 ± 14.7936.2 ± 17.2936.3 ± 10.9640.9 ± 11.4838.6 ± 12.53
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboClazakizumab (150 IV/100 SC)Clazakizumab (300 IV/100 SC)Clazakizumab (400 SC/200 SC)Clazakizumab (600 IV/200 SC)Total
Female145710945
Male4428927
08

Study locations

56 sites
  • University Of California, San Diego
    La Jolla, California 92093, United States
  • Precision Research Institute, Llc
    San Diego, California 92114, United States
  • South Denver Gastroenterology, Pc
    Lone Tree, Colorado 80124, United States
  • University Of Florida
    Gainesville, Florida 32610, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Premier Medical Group Of The Hudson Valley, Pc
    Poughkeepsie, New York 12601, United States
  • Options Health Research, Llc
    Tulsa, Oklahoma 74104, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Calgary, Alberta T2N 4Z6, Canada
  • Local Institution
    Vancouver, British Columbia V6Z 2K5, Canada
  • Local Institution
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Local Institution
    Hradec Kralove, 50012, Czechia
  • Local Institution
    Clermont-ferrand Cedex 1, 63003, France
  • Local Institution
    Lille Cedex, 59037, France
  • Local Institution
    Nice, 06200, France
  • Local Institution
    Pessac, 33600, France
  • Local Institution
    St Priest En Jarez, 42270, France
  • Local Institution
    Duesseldorf, 40237, Germany
  • Local Institution
    Frankfurt A. M, 60431, Germany
  • Local Institution
    Herne, 44623, Germany
  • Local Institution
    Kiel, 24105, Germany
  • Local Institution
    Magdeburg, 39120, Germany
  • Local Institution
    Muenster, 48155, Germany
  • Local Institution
    Hong Kong, Hong Kong
  • Local Institution
    Budapest, 1136, Hungary
  • Local Institution
    Debrecen, 4025, Hungary
  • Local Institution
    Pecs, 7623, Hungary
  • Local Institution
    Hyderabad, Andhra Pradesh 500082, India
  • Local Institution
    Mumbai, Maharashtra 400020, India
  • Local Institution
    Ludhiana, 141001, India
  • Local Institution
    Mumbai, 400 029, India
  • Local Institution
    Pune, 411030, India
  • Local Institution
    Jerusalem, 91031, Israel
  • Local Institution
    Rehovot, 76100, Israel
  • Local Institution
    Tel Aviv, 64239, Israel
  • Local Institution
    Firenze, 50134, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    Roma, 00152, Italy
  • Local Institution
    San Donato Milanese (mi), 20097, Italy
  • Local Institution
    San Giovanni Rotondo (fg), 71013, Italy
  • Local Institution
    Seoul, 120-752, Korea, Republic of
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Mexico, Distrito Federal 14080, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Nijmegen, 6500 HB, Netherlands
  • Local Institution
    Krakow, 31-864, Poland
  • Local Institution
    Lodz, 90-302, Poland
  • Local Institution
    Wroclaw, 50-556, Poland
  • Local Institution
    Wroclaw, 53-114, Poland
  • Local Institution
    Zuerich, 8091, Switzerland
  • Local Institution
    Kaohsiung, 80756, Taiwan
  • Local Institution
    Taipei, 100, Taiwan
  • Local Institution
    Hull, Kingston Upon Hull, City Of HU3 2JZ, United Kingdom
  • Local Institution
    Harrow, HA1 2UJ, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2021, 8 years after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2012
First posted
Mar 6, 2012
Start
Jun 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results delay requested
Jul 24, 2015
Results first posted
Dec 3, 2021
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01545050
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Mar 6, 2012
Start date
Jun 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Dec 3, 2021
Last update
Dec 3, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion